Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Janssen Pharmaceuticals
Information provided by (Responsible Party):
Cynthia L Gay, MD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT00855413
First received: March 2, 2009
Last updated: October 8, 2013
Last verified: October 2013

March 2, 2009
October 8, 2013
March 2009
December 2014   (final data collection date for primary outcome measure)
To measure virologic and immunologic response in AHI with DRV/R & ETR (absolute values and change from baseline, plus slope of change). [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00855413 on ClinicalTrials.gov Archive Site
To measure drug levels in various compartments with replication in cellular compartments and immunological outcome. [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
CID 0821 - Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected Antiretroviral Naïve Patients Treated With Darunavir/Ritonavir and Etravirine

Purpose: This is a pilot study to evaluate HIV viremia and persistence in acutely HIV infected antiretroviral naïve patients treated with Darunavir/ritonavir and Etravirine

Participants: 20 participants, age 18 and older, HIV infected, antiretroviral naïve patients

Procedures (methods): ARV treatment with Darunavir/ritonavir and Etravirine,

Optional studies:

Genital secretion samples, Cerebrospinal fluid samples, Leukapheresis, Endoscopy/colonoscopy

Study Design

This is a multicenter, single arm, 48-week open-label pilot study of DRV/R & ETR in acute HIV infection. Study sites will be members of the Duke-UNC Acute HIV Infection Study Consortium. If baseline resistance is detected after treatment begins (e.g. evidence of pre-existing baseline resistance (genotypic or phenotypic) that may adversely affect the efficacy of the study regimen), the patient may elect to alter treatment as per best clinical practice. The new regimen will not be provided by the study, but will be obtained for the participant through available clinical resources.

After patients are identified with acute HIV infection, they will be offered the opportunity to participate in the study. Patients will also be offered the opportunity to co-enroll in CHAVI 001 and 012, studies that follow the virological and immunological response of patients with AHI, regardless of the initiation of ART. An overall consent form will be signed for study participation, and separate informed consents with signatures will be obtained for optional studies. Patients will be eligible for participation after signing the overall consent - agreeing to participate in studies of other compartment specimens is not required for enrollment. At the initial visit, patient eligibility will be confirmed with appropriate laboratory testing (see "STUDY POPULATION"). When eligibility is verified, entry laboratory studies will be obtained, and the participants will be started on DRV/r, and ETR. All participants will be followed at regular intervals thereafter as specified in the schedule of evaluations. Participants meeting criteria for virologic failure will be offered the opportunity to switch to the best available regimen as selected by their HIV provider.

Hypothesis

Combination therapy with DRV/R & ETR will suppress plasma viremia and improve immunologic function in antiretroviral (ART)-naïve, acutely HIV-infected (AHI) patients, and will limit replication in HIV-1 cellular compartments.

Interventional
Phase 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Acute HIV Infection
  • HIV Infections
Drug: Darunavir/Ritonavir and Etravirine

DRV/r will be administered 800 mg/100 mg orally once daily.

ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen.

Other Name: Prezista, Norvir, Intelence
Darunavir/Ritonavir and Etravirine

Darunavir/Ritonavir and Etravirine

DRV/r will be administered 800 mg/100 mg orally once daily.

ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen.

Intervention: Drug: Darunavir/Ritonavir and Etravirine
  • C Gay, A Johnson, S McCoy, J Kuruc, K McGee, L McNeil, M Kerkau, J Sebastian, C Pilcher, D Margolis, P Leone, S Fiscus, G Ferrari, C Hicks, J Eron, The Duke-UNC Acute HIV Infection Consortium. "Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection." XVII International AIDS Conference, 2008 Abstract no. THPE0082.
  • C Gay, O Dibben, A Stacey, N Gasper-Smith, M Liu, N Goonetilleke, G Ferrari, J Eron, C Hicks, A McMichael, B Haynes, P Borrow, M Cohen, the Duke-UNC CHAVI 001 Clinical Working Group. "Effect(s) of antiretroviral treatment on acute HIV infection." XVII International AIDS Conference, 2008 Abstract no. THPE0086.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
December 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Documentation of Acute HIV Infection as defined above.
  2. Men and women age ≥18 years.
  3. Participants will be ART naïve, defined as ≤14 days of antiretroviral treatment at any time prior to entry. The only exceptions are: Post-exposure prophylaxis (PEP) provided the patient was documented as HIV-1 negative at least 3-6 months after completion of the PEP treatment.
  4. Screening HIV-1 RNA >1,000 copies/mL obtained within 30 days at study entry.
  5. Lab values obtained within 30 days prior to study entry:
  6. Absolute neutrophil count >500/mm3
  7. Hemoglobin > 8.5 g/dL for men and > 8.0 g/dL for women
  8. Platelet count >50,000/mm3
  9. AST (SGOT) ≤2.5 x ULN
  10. ALT (SGPT) ≤2.5 x ULN
  11. Total bilirubin <2.5 x ULN
  12. Calculated creatinine clearance (Cockcroft-Gault formula) > 30mL/min:

    • CrCl = (140-age) x body weight (kg) (x 0.85 if female)
    • Serum creatinine [mg/dL] x (72)
  13. For women of reproductive potential, a negative serum or urine pregnancy test within 7 days prior to initiating antiretroviral study medications. Reproductive potential is defined as females who have reached menarche and have not been post-menopausal for at least 24 consecutive months, or have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or salpingotomy). Acceptable documentation of surgical sterilization includes patient-reported history.
  14. If participating in sexual activity that could lead to pregnancy, female study patients must use at least one form of contraception, which could consist only of a barrier method. All patients must continue to use contraception for 6 weeks after stopping the study medications. Acceptable methods of contraception include: condoms (male or female) with or without spermicidal agent, diaphragm or cervical cap with spermicide, or IUD. Female volunteers not of reproductive potential are not required to use contraception.
  15. Ability and willingness of patient to give written informed consent.

Exclusion Criteria:

  1. Women who are pregnant or breast-feeding.
  2. Women with a positive pregnancy test on enrollment or prior to study drug administration.
  3. Women of reproductive potential who are unwilling or unable to use acceptable methods to avoid pregnancy for the entire study period
  4. Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry.

    • Prednisone at a daily dose of 10 mg or less (physiologic replacement dose) is permitted.
  5. Known allergy/sensitivity to study drugs or their formulations.
  6. Difficulty swallowing capsules/tablets.
  7. Inability to communicate effectively with study personnel.
  8. Incarceration; prisoner recruitment and participation are not permitted.
  9. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements or confound the analysis of study endpoints.
  10. Any active psychiatric illness including schizophrenia, severe depression, or severe bipolar affective disorder that, in the opinion of the investigator, could confound the analysis of the neurological examination or neuropsychological test results.
  11. Active brain infection (except for HIV-1), brain neoplasm, space-occupying brain lesion requiring acute or chronic therapy. Participants with any fungal meningitis, parasitic infection, or CNS lymphoma are excluded from participation.
  12. Serious illness requiring systemic treatment and/or hospitalization until patient either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry. NOTE: Oral candidiasis, vaginal candidiasis, mucocutaneous herpes simplex, and other minor illnesses (as judged by the site investigator) have no restriction.
  13. Known cardiac conduction disease.
  14. Prior treatment with any other experimental drug for any indication (within 30 days of initiating study treatment).
  15. Unable to discontinue any current medications that are excluded during study treatment.
  16. A life expectancy less than twelve months.
  17. Acute Viral Hepatitis, including, but not limited to, Hepatitis A, B, or C
  18. Chronic Hepatitis B Infection documented by a detectable serum Hepatitis B surface antigen (HBsAg) or plasma HBV DNA
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00855413
CID 0821
Yes
Cynthia L Gay, MD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
Janssen Pharmaceuticals
Principal Investigator: Cynthia Gay, MD, MPH University of North Carolina, Chapel Hill
Principal Investigator: David M Margolis, MD University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP